GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoVista Innovative Therapies Inc (OTCPK:OVIT) » Definitions » Book Value per Share

OVIT (OncoVista Innovative Therapies) Book Value per Share : $-0.28 (As of Sep. 2015)


View and export this data going back to 2005. Start your Free Trial

What is OncoVista Innovative Therapies Book Value per Share?

OncoVista Innovative Therapies's book value per share for the quarter that ended in Sep. 2015 was $-0.28.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

OncoVista Innovative Therapies's current price is $0.0001. Its book value per share for the quarter that ended in Sep. 2015 was $-0.28. Hence, today's PB Ratio of OncoVista Innovative Therapies is .


OncoVista Innovative Therapies Book Value per Share Historical Data

The historical data trend for OncoVista Innovative Therapies's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoVista Innovative Therapies Book Value per Share Chart

OncoVista Innovative Therapies Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 -0.01 -0.08 -0.14 -0.26

OncoVista Innovative Therapies Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.26 -0.27 -0.32 -0.28

Competitive Comparison of OncoVista Innovative Therapies's Book Value per Share

For the Biotechnology subindustry, OncoVista Innovative Therapies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoVista Innovative Therapies's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoVista Innovative Therapies's PB Ratio distribution charts can be found below:

* The bar in red indicates where OncoVista Innovative Therapies's PB Ratio falls into.



OncoVista Innovative Therapies Book Value per Share Calculation

OncoVista Innovative Therapies's Book Value Per Share for the fiscal year that ended in Dec. 2014 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.66-0.00)/22.01
=-0.26

OncoVista Innovative Therapies's Book Value Per Share for the quarter that ended in Sep. 2015 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.59-0.00)/23.56
=-0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


OncoVista Innovative Therapies  (OTCPK:OVIT) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


OncoVista Innovative Therapies Book Value per Share Related Terms

Thank you for viewing the detailed overview of OncoVista Innovative Therapies's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoVista Innovative Therapies Business Description

Traded in Other Exchanges
N/A
Address
14785 Omicron Drive, Suite 104, San Antonio, TX, USA, 78245
OncoVista Innovative Therapies Inc is a biopharmaceutical company. It is engaged in developing anticancer therapies by utilizing tumor-associated biomarkers.
Executives
Alexander Ruckdaeschel director 123 EAST 83RD STREET, APT 3-B, NEW YORK NY 10028
Paul A Mieyal director C/O WEXFORD CAPITAL LP, 411 WEST PUTNAM AVE, SUITE 125, GREENWICH CT 06830
Charles E Davidson 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602, WEST PALM BEACH FL 33401
Wexford Capital Lp 10 percent owner 777 WEST PUTNAM AVENUE, 1ST FLOOR, GREENWICH CT 06830
Joseph Jacobs 10 percent owner C/O WEXFORD CAPITAL LP, 777 SOUTH FLAGLER DRIVE, SUITE 602 EAST, WEST PALM BEACH FL 33401
Wexford Spectrum Trading Ltd 10 percent owner 411 WEST PUTNAM AVENUE, SUITE 125, GREENWICH CT 06830

OncoVista Innovative Therapies Headlines

No Headlines